Sarepta Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
23analysts covering
FY Revenue (est.)
$1.8Bnext fiscal year
FY EPS (est.)
$4.39next fiscal year
Monitoring Framework
Key Performance Indicators
ELEVIDYS Net Product Revenue Quarterly102MTarget: Exceed $500 million yearly sales floor
PMO Franchise Net Product Revenue Quarterly228.6MTarget: Maintain stable durable revenue
Total Net Product Revenues Guidance Annually330.5MTarget: $1.2 billion - $1.4 billion for FY 2026
Watch Items
- Regulatory conversion of AMONDYS 45 and VYONDYS 53 to traditional approvalsTrigger: FDA decision on sNDAs submitted in April 2026Action: Monitor FDA communication and update commercial projections
- CEO Succession ProcessTrigger: Appointment of successor to Douglas IngramAction: Evaluate transition timeline and strategic continuity
- siRNA Pipeline Clinical Progress (SRP-1001 and SRP-1003)Trigger: Phase 1/2 data readouts and dose-escalation milestonesAction: Assess therapeutic efficacy and safety profile to validate next-generation platform
Research as of 20 Jun 2026